AFM
CELZ icon

Anson Funds Management’s Creative Medical Technology CELZ Stock Holding History

Anson Funds Management’s Portfolio CELZ Stock Details CELZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$153K Buy
+105,549
New +$228K 0.01% 163

Other funds holding CELZ

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Anson Funds Management's CELZ Position: Q2 2026 in Review

Anson Funds Management opened a new position in Creative Medical Technology (CELZ) in Q2 2026: 105,549 shares worth $153K. The stake represents 0.01% of the portfolio and ranks #163 among its holdings.

14 funds tracked by Wall St. Rank hold CELZ as of Q2 2026.

  • Anson Funds Management held 105,549 shares of Creative Medical Technology worth $153K as of Q2 2026.
  • Creative Medical Technology was a new Anson Funds Management position in Q2 2026.
  • Creative Medical Technology made up 0.01% of Anson Funds Management's portfolio in Q2 2026, its #163 holding.
  • 14 funds tracked by Wall St. Rank held Creative Medical Technology as of Q2 2026.

Based on Anson Funds Management's 13F filing for Q2 2026, filed 13 Aug 2026.